Field Notes & FAQ — ten questions, answered straight

Bromantane (ADK-709, trade name Ladasten) is an actoprotector — a synthetic adaptogen — developed in Russia. Chemically it is an adamantane-derived secondary amine that supports endurance and anti-fatigue capacity by upregulating tyrosine hydroxylase, the body's own dopamine-synthesis enzyme, rather than by forced stimulation.

Not in the classic sense. Actoprotectors are agents of non-exhaustive action: bromantane raises dopamine synthesis and release in animal and microdialysis studies, but monoamine reuptake inhibition appears only at concentrations far above clinical relevance, and the Russian clinical trials report no hyperstimulation and no withdrawal after discontinuation.

Yes — in Russia it is an approved prescription medicine (Ladasten, 50 mg tablets) for asthenic disorders. It is not FDA-approved and holds no EU or UK marketing authorisation; outside Russia it circulates as a research compound. It has also been prohibited in sport since 1997.

The available evidence says no: the placebo-controlled neurasthenia trial recorded no withdrawal syndrome after discontinuation, and chronic animal administration produced neither dependence nor tolerance. Nearly all of these data are Russian; no Western regulatory-grade safety database exists.

Actoprotectors are defined as preparations that enhance body stability against physical loads without increasing oxygen consumption or heat production — synthetic adaptogens with a significant capacity to improve physical performance. The class was developed in the USSR for space, sports and military medicine; bromantane and bemitil (Metaprot) are its two classics. Their defining trait is non-exhaustive action: endurance without the stimulant crash.

The Russian clinical trials used 50–100 mg per day for up to 28 days under medical supervision, and the Russian label markets 50 mg tablets. This journal is a scientific monograph, not a dosing guide: outside Russia bromantane is an unapproved research compound, and any decision about use belongs with a qualified physician who knows your history. Nothing here is medical advice.

Because it works on the very axis sport protects. Several Russian athletes tested positive at the 1996 Atlanta Olympics; French researchers reported Bromontan, a new doping agent, in The Lancet in 1997, and prohibition followed from 1997. Its metabolites remain detectable in urine for two weeks or more, which made it a landmark case in doping-control chemistry. Athletes subject to testing should treat it as prohibited, full stop.

No source this journal could check ties bromantane itself to space use. The documented cosmonaut actoprotector was bemitil — the first recipients of bemitil were Soviet cosmonauts, per the actoprotector review. The cosmonaut-bromantane story is a marketing embellishment that conflates the two compounds, and this journal declines to repeat it.

In the 728-patient trial, adverse effects occurred in 3% of patients and discontinuation in 0.8%, with no serious adverse events at 50–100 mg per day over 28 days; Russian prescribing information lists insomnia and hyperactivation as possible effects. Animal toxicity appeared only at very high doses. The important caveat: nearly all safety data are Russian, and no Western regulatory-grade safety database exists.

As a student of it. Russian science created bromantane; Panacea Bio Chem honours that origin and is investigating the compound within its molecular-performance and formulation research programme — an ongoing investigation with no results claimed yet. The programme's scope is described on The Panacea Programme page of this journal.

Almost nothing, on principle. A small cookieless beacon counts page views and time on page, and records the referring site, language and coarse screen size. No cookies, no fingerprinting, no third parties — and your IP address is never stored, only a salted daily-rotating hash that counts unique visitors for a single day. Browsers set to Do Not Track send nothing at all.